Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00005095
Status:
RECRUITING
Last Update Posted:
2023-06-18
First Post:
2000-04-06
Brief Title:
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Northwestern Ovarian Cancer Early Detection Prevention Program A Specimen and Data Study
Status:
RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE To improve strategies for detection and prevention of early-stage disease
PURPOSE This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease
PURPOSE This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease
Detailed Description:
OBJECTIVES
To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies
To identify new prevention approaches and therapies
To identify measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
OUTLINE Subjects undergo periodic specimen and data collection for research studies including molecular biochemical functional and genetic marker studies Participants may have samples of blood tissue or body fluids such as ascites pleural fluid or urine or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer
The results from the biomarker research studies will not be reported to the patient or the physician In the future if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer and the patients result is abnormal the patient and physician will be notified
Subjects may be asked to complete a combination of questionnaires designed to evaluate psychological functioning among women enrolled in a comprehensive ovarian cancer early detection program who are at increased risk for developing disease as compared to women currently diagnosed with ovarian cancer
To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies
To identify new prevention approaches and therapies
To identify measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
OUTLINE Subjects undergo periodic specimen and data collection for research studies including molecular biochemical functional and genetic marker studies Participants may have samples of blood tissue or body fluids such as ascites pleural fluid or urine or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer
The results from the biomarker research studies will not be reported to the patient or the physician In the future if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer and the patients result is abnormal the patient and physician will be notified
Subjects may be asked to complete a combination of questionnaires designed to evaluate psychological functioning among women enrolled in a comprehensive ovarian cancer early detection program who are at increased risk for developing disease as compared to women currently diagnosed with ovarian cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1753 | OTHER_GRANT | NCI | httpsreporternihgovquickSearchP30CA060553 |
| P30CA060553 | NIH | None | None |
| NU-99G8 | OTHER | None | None |